|
|
Vaccine Detail
|
MART-1:26-35(27L) Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1:26-35(27L) Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007506
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description: MLANA, also known as MART-1, was used as one vaccine antigen for the cancer vaccine (Keller et al., 2015).
- Detailed Gene Information: Click Here.
- gp100 (PMEL)
gene engineering:
- Description: NULL
|
| Host Response |
|
|
| References |
Keller et al., 2015: Keller M, Ebstein F, Bürger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krüger E, Rothkötter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U. The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition. European journal of immunology. 2015; 45(12); 3257-3268. [PubMed: 26399368].
|
|
